Capturing the Complexity of the Human Gut

Our goal is to enable pharmaceutical companies to identify effective compounds earlier, before clinical trials; to reduce animal testing; and to make the drug development process faster, cheaper, and safer.

Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. The product is called RepliGut. It will allow drugs to be tested on an in vitro platform that more closely mimics native human biology. Our goal is to enable pharmaceutical companies to identify effective compounds earlier, before clinical trials; to reduce animal testing; and to make the drug development process faster, cheaper, and safer.

4.9 out of 5 stars from 47 reviews
4.7/5

RepliGut Systems - The next generation of gut models

Our flagship RepliGut® Planar models advance novel pharmaceuticals by harnessing the potential of human donor intestinal stem cells. These cells undergo a process of sequential proliferation and differentiation, ultimately transforming into the essential cell types found in the human gastrointestinal epithelium for use in drug discovery and development.

GI Toxicity

Screen compounds for drug-induced GI toxicity early

Intestinal Barrier Function

Maintains barrier integrity with high TEER values

Inflammatory Response

Comprised of polarized intestinal cells grown on transwells

Intestinal Drug Disposition

Developed to replace Caco-2 cells (cancer cells) and animals

The current lack of user-friendly pre-clinical pharmacological testing models

Our Mission

Altis’ mission is to provide scientific innovation, through collaborative relationships, by helping companies develop safer and more effective therapies to treat patients suffering from human disease. We support life science researchers by providing expertise and unique in vitro platforms to further their research and increase their understanding of human biology, while reducing the need for animal testing

A need for better models

In order to successfully advance a novel therapy through the drug development pipeline, it is crucial to select an appropriate model system early on. Model systems provide us with valuable insights into disease mechanisms and enable effective evaluation of potential treatments. However, the current lack of user-friendly pre-clinical pharmacological testing models for the human intestine significantly hinders our ability to develop new therapies for intestinal disorders. Additionally, it presents a challenge in ensuring the safe passage of orally administered treatments for other conditions through the gut without  unwanted side effects.

microbiome research
Cell-based
In order to successfully advance a novel therapy
Altis Biosystems has pioneered the creation of Repligut® Systems

Pioneering Technology

Altis Biosystems has pioneered the creation of Repligut® Systems, a collection of in vitro models derived from stem cells and designed specifically for pre-clinical drug discovery. These innovative systems overcome the constraints of conventional cell lines and animal models, providing a highly accurate representation of human intestinal physiology.

user friendly
preclinical insights
0
Years since start
+ 0
Happy clients
+ 0
Projects completed
+ 0
Kits delivered

Establishment of RepliGut® Planar Models

Step 1

We source human intestinal epithelial stem cells from donor tissue while upholding ethical standards

Step 2

By expanding these stem cells, we can create a cryopreserved biobank that allows for multiple studies using the same donor.

Step 3

Our biobanked cells are carefully thawed and then directly seeded onto a semi-permeable membrane coated with a biomimetic scaffold.

Our Experience Is Your Advantage

See how our clients are using RepliGut Systems

Ready to Go With Your Gut?

Contact us to learn more about RepliGut® Model Kits and Services.